UAE Dermatology Drugs Market Analysis Report 2022 to 2030

UAE Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the UAE Dermatology drugs market will reach a value of $207.47 Mn from $85 Mn in 2022, growing at a CAGR of 11.8% during 2022-2030. The market is primarily dominated by local players such as Gulf Pharmaceutical Industries, Neopharma, and Julphar. The market is driven by slow research and development, increasing disease prevalence, and government regulations. The dermatology drug market in UAE is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.

ID: IN10AEPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Dr. Vishwa Modhia

Buy Now

UAE Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the UAE Dermatology drugs market will reach a value of $207.47 Mn from $85 Mn in 2022, growing at a CAGR of 11.8% during 2022-30.

In the UAE, the frequency of dermatological conditions is rising. For instance, acne affects 9.4% of people (including 41% of women). Other ailments include psoriasis, dry skin, rosacea, eczema, and itchy patches. The UAE is now a centre for medical innovation and research thanks to the large number of international healthcare companies that have drawn there.

As of 2021, the UAE's healthcare industry made up about 6% of the country's total Gross Domestic Product (GDP). The UAE government has made significant investments in the development of telemedicine and electronic health record systems, as well as in the construction of contemporary hospitals and clinics. The nation boasts a sizable number of both public and private healthcare facilities and is renowned for its top-notch medical tourism sector.

uae dermatology drugs market analysis

Market Dynamics

Market Growth Drivers Analysis

The harsh climate in the UAE can affect the skin and increase the occurrence of skin conditions like sunburn and skin cancer. It has high levels of heat, humidity, and UV radiation. This could increase demand for some dermatology procedures. Skin allergies are becoming more common in the UAE, which is caused by things like environmental pollution and increased exposure to chemicals and pollutants. As a result, there is now greater demand for dermatology medications and procedures that can lessen the signs and symptoms of skin allergies and support healthy skin.

Market Restraints

The UAE government provides reimbursement for some medical treatments, but the exact level of reimbursement can vary depending on the specific treatment and the individual's insurance coverage. This may limit some patients' access to the most recent therapies and technologies by affecting the cost of their treatments.

Competitive Landscape

Key Players

Julphar (ARE)
Neopharma (ARE)
Gulf Pharmaceutical Industries (Julie) (ARE)
GlaxoSmithKline
Pfizer
Sanofi
Johnson & Johnson

Recent Notable Updates

March 2022: Dubai Derma 2022, the world's largest dermatology and laser conference and exhibition represented a significant advance by registering numerous direct and indirect business deals. The event's capacity to provide a platform for new partnerships and investment opportunities for regional and international companies is highlighted by the event's record-breaking volume of business deals.

Healthcare Regulations and Reimbursement Policies

The UAE regulates the pharmaceutical industry, including the dermatology drug market, through the Ministry of Health and Prevention (MOHP). The MOHP is responsible for ensuring the safety, efficacy, and quality of all pharmaceutical products sold in the UAE, including dermatology drugs.

In the UAE, the reimbursement of dermatology drugs varies depending on the type of insurance coverage a patient has. The two main types of insurance in the UAE are private insurance, which covers more drugs, and public insurance, having limited reimbursement.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.